(S1 (S (NP (NP (NN Relationship)) (PP (IN of) (NP (NP (NN p53)) (CC and) (NP (NN Helicobacter) (NN pylori)))) (PP (TO to) (NP (NP (JJ clinicopathological) (NNS features)) (PP (IN of) (NP (JJ human) (JJ remnant) (NN stomach) (NN cancer))) (PP (IN after) (NP (NP (JJ gastric) (NN surgery)) (PP (IN for) (NP (JJ primary) (JJ gastric) (NN cancer))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ biological) (NNS features)) (PP (IN of) (NP (NP (JJ gastric) (NN cancer)) (PP (IN of) (NP (NP (DT the) (JJ remnant) (NN stomach)) (PRN (-LRB- -LRB-) (NP (NN RSC)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (NN Twenty-one) (NNS patients)) (VP (VP (VBD underwent) (NP (NP (NN resection)) (PP (IN of) (NP (DT the) (JJ remnant) (NN stomach))) (PP (IN for) (NP (NN RSC))))) (CC and) (VP (VBD were) (VP (VBN divided) (PP (IN into) (NP (NP (CD two) (NNS groups)) (: :) (S (S (NP (DT the) (NN RSCB) (NN group)) (VP (VBD consisted) (PP (IN of) (NP (NP (CD 11) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NP (JJ distal) (NN gastrectomy)) (PP (IN for) (NP (JJ benign) (NN disease))))))))))) (CC and) (S (NP (DT the) (NN RSCM) (NN group)) (VP (VBD consisted) (PP (IN of) (NP (NP (CD 10) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NP (NN gastrectomy)) (PP (IN for) (NP (JJ primary) (JJ gastric) (NN cancer)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interval)) (PP (IN between) (NP (NP (JJ primary) (NN surgery)) (CC and) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (JJ gastric) (NN cancer))) (PP (IN in) (NP (DT the) (JJ remnant) (NN stomach))))))) (VP (VBD was) (ADJP (ADJP (RB significantly) (JJR shorter)) (PP (IN in) (NP (DT the) (NN RSCM) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (NN RSCB) (NN group))))))) (. .)))
(S1 (S (S (S (NP (NP (NN Invasion)) (PP (IN of) (NP (JJ adjacent) (NNS organs)))) (VP (VBD was) (ADJP (RBR more) (JJ frequent)) (PP (IN in) (NP (DT the) (NN RSCM) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (NN RSCB) (NN group)))))) (CC and) (S (NP (NP (DT the) (NN Ki-67) (NN labeling) (NN index)) (PP (IN of) (NP (DT the) (NNS tumors)))) (VP (VBD was) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (DT the) (JJ former) (NN group)))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN p53) (NN overexpression)) (PP (IN by) (NP (NNS tumors)))) (VP (VBD was) (ADVP (RB almost) (RB twice)) (ADJP (RB as) (JJ common) (PP (IN in) (NP (NP (DT the) (NN RSCM) (NN group)) (PP (IN as) (PP (IN in) (NP (DT the) (NN RSCB) (NN group))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN of) (NP (DT the) (NNP H.) (NNP pylori) (NN positivity))) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))))) (, ,) (NP (NP (DT the) (NN rate)) (PP (IN for) (NP (DT both) (NNS groups)))) (VP (VBD was) (ADJP (ADJP (JJR higher)) (SBAR (IN than) (S (VP (VBN reported) (PP (IN in) (NP (JJ previous) (NNS studies))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN Mutation)) (PP (IN of) (NP (NN p53)))) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ high) (JJ proliferative) (NN activity)) (PP (IN of) (NP (NNS tumors))) (PP (IN in) (NP (DT the) (NN RSCM) (NN group)))))))) (CC and) (S (NP (NNP H.) (NN pylori) (NN infection)) (VP (MD may) (VP (VB be) (ADJP (RB closely) (JJ related) (PP (TO to) (NP (NP (NN carcinogenesis)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN RSC)))))))))))) (. .)))
